Is Winlevi Safe for Long Term Use?
Winlevi is a topical cream containing clascoterone 1% that the FDA approved for treating acne vulgaris. The drug works by blocking androgen receptors on the skin, which helps reduce acne breakouts. Since its approval in 2020, Winlevi has become the number one most prescribed topical acne brand in the United States, suggesting that doctors and patients have found it to be a reliable treatment option.
When it comes to safety, the clinical trials that led to Winlevi’s approval showed a favorable safety profile. Between 7 and 12 percent of users reported mild side effects like redness, itching, and scaling at the application site. These local skin reactions were generally comparable to placebo in the trials. More serious concerns like hyperkalemia and HPA axis suppression could theoretically occur, but these events are rare based on the available data.
One of the key advantages of Winlevi is that it acts locally on the skin rather than being absorbed systemically into the bloodstream. Because clascoterone is metabolized quickly and does not enter the body in significant amounts, the risk of systemic hormonal side effects appears to be low. Clinical data from the acne trials showed no significant suppression of systemic hormone markers, even after weeks of regular application.
However, there is an important distinction to make. Winlevi contains clascoterone at a 1% concentration and was tested and approved specifically for acne treatment. Some people have attempted to use Winlevi off-label on their scalps to treat hair loss, but experts question whether this approach is effective. The dose may be too low for hair loss treatment, and the way the cream is absorbed by the scalp could be completely different from how it is absorbed by facial skin where acne occurs.
Cosmo Pharmaceuticals, the company behind Winlevi, has been developing a higher-concentration clascoterone 5% topical solution specifically for male pattern hair loss. This stronger formulation is currently in Phase III clinical trials and has not yet been approved by the FDA. The Phase III trials for the 5% solution ran for only 6 months, with an open-label extension for responders. Long-term safety data beyond this timeframe does not yet exist for the higher-concentration product.
For the original Winlevi 1% cream used as approved for acne, long-term safety appears reasonable based on the clinical trial data and its track record as the most prescribed topical acne medication in the country. Patients have been using it since 2020 without widespread reports of serious safety concerns. That said, individual responses can vary, and anyone considering long-term use should discuss potential risks and benefits with a dermatologist.
The situation becomes more uncertain when considering off-label use or the experimental higher-concentration formulation. Until the 5% clascoterone solution completes its full regulatory review and receives approval, questions about its long-term safety profile in hair loss treatment remain unanswered. Cosmo expects to complete required 12-month safety follow-up data in spring 2026 and plans to submit applications to the FDA and European regulatory agencies thereafter.
In summary, Winlevi at its approved 1% concentration for acne appears to have an acceptable safety profile based on clinical trials and real-world use over several years. However, long-term safety data extending beyond several years does not exist for any formulation of clascoterone. Anyone considering extended use should consult with a healthcare provider about their individual risk factors and whether the benefits justify any potential risks.
Sources
https://www.hairlosscure2020.com/breezula-clascoterone-breakthrough-phase-iii-results/
https://www.aditharun.com/p/clascoterone-is-not-a-cure-for-baldness
https://clinicaltrials.gov/study/NCT05914805
https://www.valuationlab.com/app/download/8251359062/Cosmo+FU+24JU
